Aselizumab: A Comprehensive Investigation into HuDreg-55
Aselizumab, also known as HuDreg-55, represents a innovative monoclonal antibody developed to interact with C1q. Its mode of action involves modulating the initial complement pathway, likely providing clinical advantage in a range of autoimmune disorders. Prior studies suggest its potential to de